Episode
Beyond BCMA: How GPRC5D-Targeted Therapy Fits Iinto Multiple Myeloma Care Today
- Published
- Jul 14, 2026
- Duration seconds
- 1614
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Targeted therapies are becoming more common treatment options for patients with multiple myeloma. Specifically, there have been emerging clinical data on GPRC5D-directed bispecific antibodies for patients with relapsed and refractory disease. In this podcast, 2 experts in the field discuss how they are using GPRC5D-directed therapies in their practice, including treatment planning, patient selection, adverse event management, and how new combination strategies may affect practice.